Long acting β2-adrenergic agonists in treatment of asthma and chronic obstructive pulmonary disease (COPD);De plaats van langwerkende β2-adrenerge agonisten in de behandeling van astma en chronische obstructieve longziekte (COPD)

Nederlands Tijdschrift voor Geneeskunde

Volumn 143, Issue 3, 1999, Pages 137-140

  Van Schayck, C P ^a,b   Postma, D S ^a   Lammers, J W ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FORMOTEROL; SALMETEROL;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DYSPNEA; HUMAN; LUNG FUNCTION; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; WALKING;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINES; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE;

EID: 0033573702     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Miller BD, Strunk RC. Circumstances surrounding the deaths of children due to asthma. A case-control study. Am J Dis Child 1989;143:1294-9.
2. Crane J, Pearee N, Flatt A, Burgess C, Jackson R, Kwong T, et al. Prescribed fenoterol and death from asthma in New Zealand. 1981-83: case-control study. Lancet 1989;1:917-22.
3. Pearee N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand. 1977-81. Thorax 1990;45:170-5.
4. Grainger J, Woodman K, Pearee N, Crane J, Burgess C, Keane A, et al. Prescribed fenoterol and death from asthma in New Zealand. 1981-87: a further case-control study. Thorax 1991;46:105-11.
5. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
6. Mullen M, Mullen B, Carey M. The association between beta-agonist use and death from asthma. A meta-analytic integration of case-control studies. JAMA 1993;270:1842-5.
7. Sears MR, Taylor DR, Print CO, Lake DC, Li QQ, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
8. Schayck CP van, Dompeling E, Herwaarden CLA van, Folgering H, Verbeek AL, Hoogen HJ van der, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991;303:1426-31.
9. Town GI, O'Donnell TV, Purdie G. Bronchial responsiveness during regular fenoterol therapy: four months prospective study. N Z Med J 1991;104:3-5.
10. Booth H, Fishwick K, Harkawat R, Devereux G, Hendrick DJ, Walters EH. Changes in methacholinc induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients. Thorax 1993;48:1121-4.
11. Schayck CP van, Dompeling E, Herwaarden CLA van, Folgering H, Akkermans RP, Broek PJ van den, et al. Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: four-year follow-up randomized controlled study. Br J Gen Pract 1995;45:239-44.
12. Molen T van der, Postma DS, Turner MO, Meyboom-de Jong B, Malo JL, Chapman K, et al. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corlicosteroids. The Netherlands and Canadian Formoterol Study Investigators. Thorax 1997;52:535-9.
13. Schayck CP van, Graafsma SJ, Visch MB, Dompeling E, Weel C van, Herwaarden CLA van. Increased bronchial hyperresponsiveness after inhaling salbutamol during I year is not caused by subsensitization tosalbutamol. J Allergy Clin Immunol 1990;86:793-800.
14. Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198-203.
15. Arvidsson P, Larsson S, Lofdahl CG, Melander B, Svedmyr N, Wahlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991;4:1168-73.
16. Geijer RMM, Hensbergen W van, Bottema BJ AM, Schayck CP van, Sachs APE, Smeele IJM, et al. NHG-standaard Astma bij volwassenen: behandeling. Huisarts Wet 1997;40:443-54.
17. Dirksen WJ, Geijer RMM, Haan M de, Roiling G de, Flikweert S, Kolnaar BGM. NHG-standaard Astma bij kinderen. Huisarts Wet 1998;41:130-43.
18. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corlicosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24.
19. Woolcock A, Lundhack B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
20. Pauwels RA, Lofdahl CO, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and hudesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
21. Geijer RMM, Schayck CP van, Weel C van, Sachs APE, Zwan AAC van der, Bottema BJAM, et al. NHG-standaard COPD: behandeling. Huisarts Wet 1997;40:430-42.
22. Cazzola M, Santangelo G, Piccolo A, Salzillo A, Matera MG, D'Amato G, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994;7:103-7.
23. Matera MG, Cazzola M, Vinciguerra A, Di Perna F, Calderaro F, Caputi M, et al. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1995;8:267-71.
24. Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995;50:750-4.
25. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997;112:336-40.
26. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-9.
27. Maesen BLP, Westermann CJJ, Duurkens VAM, Bosch JMM. Formoterol induced responses in non-reversible chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;155:A282.
28. Tutluoglu B, Gurhuz N, Sahin S, Abanoziu S, Ozden S, Effects of short term usage of formoterol on six minute walking test in COPD patients. Eur Respir J 1997;10(Suppl 25):65S.
29. Barnes PJ, Belvisi MG, Mak JCW, Hadda E, O'Connor B. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995;56:853-9.
30. Maesen FPV, Smeets JJ, Sledsens TJH, Wald FDM, Cornelissen PJG. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995;8:1506-13.